{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T04:23:57Z","timestamp":1791260637024,"version":"4.1.0"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2001,1,1]],"date-time":"2001-01-01T00:00:00Z","timestamp":978307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,24]],"date-time":"2019-12-24T00:00:00Z","timestamp":1577145600000},"content-version":"vor","delay-in-days":6931,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2001]]},"DOI":"10.1093\/annonc\/12.suppl_1.s15","type":"journal-article","created":{"date-parts":[[2012,1,20]],"date-time":"2012-01-20T05:04:11Z","timestamp":1327035851000},"page":"S15-S19","source":"Crossref","is-referenced-by-count":97,"special_numbering":"S1","title":["HER2 overexpression in various tumor types, focussing on its relationship to the development of invasive breast cancer"],"prefix":"10.1016","volume":"12","author":[{"given":"S.","family":"M\u00e9nard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Casalini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Campiglio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Pupa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Agresti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Tagliabue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/12.suppl_1.S15_bb0010","first-page":"165","article-title":"The biology of erbB-2\/neu\/HER-2 and its role in cancer","volume":"1198","author":"Hynes","year":"1994","journal-title":"Biochem Biophys Acta"},{"key":"10.1093\/annonc\/12.suppl_1.S15_bb0015","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1126\/science.2470152","article-title":"Studies of the HER-2\/neu proto-oncogene in breast and ovarian cancer","volume":"244","author":"Slamon","year":"1989","journal-title":"Science"},{"key":"10.1093\/annonc\/12.suppl_1.S15_bb0020","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1002\/1097-0142(19921115)70:10<2493::AID-CNCR2820701017>3.0.CO;2-K","article-title":"An immunohistologic evaluation of c-erbB-2 gene product in patients with urinary bladder carcinoma","volume":"70","author":"Sato","year":"1992","journal-title":"Cancer"},{"key":"10.1093\/annonc\/12.suppl_1.S15_bb0025","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/BF02788354","article-title":"Overexpression of HER2\/neu oncogene in pancreatic cancer correlates with shortened survival","volume":"17","author":"Lei","year":"1995","journal-title":"Int J Pancreatol"},{"key":"10.1093\/annonc\/12.suppl_1.S15_bb0030","first-page":"5184","article-title":"p185neu expression in human lung adenocarcinomas predicts shortened survival","volume":"50","author":"Kern","year":"1990","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/12.suppl_1.S15_bb0035","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1001\/archotol.1995.01890110041008","article-title":"HER-2\/neu oncogene characterization in head and neck squamous-cell carcinoma","volume":"121","author":"Beckhardt","year":"1995","journal-title":"Arch Otolaryngol Head Neck Surg"},{"key":"10.1093\/annonc\/12.suppl_1.S15_bb0040","first-page":"2771","article-title":"Sensitivity of HER2\/neu antibodies in archival tissue samples: Potential source of error in immunohistochemical studies of oncogene expression","volume":"54","author":"Press","year":"1994","journal-title":"Cancer Res"},{"issue":"Suppl 1","key":"10.1093\/annonc\/12.suppl_1.S15_bb0045","doi-asserted-by":"crossref","first-page":"S97","DOI":"10.1093\/annonc\/12.suppl_1.S97","article-title":"Current use of HER2 tests","volume":"12","author":"Schaller","year":"2001","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/12.suppl_1.S15_bb0050","first-page":"1247","article-title":"The combination of in situ hybridization and immunohistochemical analysis: An evaluation of HER2\/neu expression in paraffin-embedded breast carcinoma and adjacent normal-appearing breast epithelium","volume":"10","author":"Ratcliffe","year":"1997","journal-title":"Mod Pathol"},{"key":"10.1093\/annonc\/12.suppl_1.S15_bb0055","first-page":"140a","article-title":"Circulating HER2\/neu predicts resistance to Taxol\u2013adriamycin in metastatic breast carcinoma: Preliminary results of a multicentric prospective study","volume":"16","author":"Colomer","year":"1997","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1093\/annonc\/12.suppl_1.S15_bb0060","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1002\/jcb.240390208","article-title":"Overexpression of the c-erbB-2 protein in human breast tumour cell lines","volume":"39","author":"Hynes","year":"1989","journal-title":"J Cell Biochem"},{"key":"10.1093\/annonc\/12.suppl_1.S15_bb0065","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1002\/j.1460-2075.1987.tb04797.x","article-title":"Overexpression of the EGF receptor-related proto-oncogene erbB-2 in human mammary tumour cell lines by different molecular mechanisms","volume":"6","author":"Kraus","year":"1987","journal-title":"EMBO J"},{"key":"10.1093\/annonc\/12.suppl_1.S15_bb0070","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1200\/JCO.1999.17.5.1644g","article-title":"Immunohistochemical assays for HER2 overexpression","volume":"17","author":"Maia","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/12.suppl_1.S15_bb0075","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1200\/JCO.1999.17.1.434","article-title":"Increased HER2 with US Food and Drug Administration-approved antibody","volume":"17","author":"Roche","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/12.suppl_1.S15_bb0080","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1093\/oxfordjournals.annonc.a058663","article-title":"Overexpression of p185 is not related to erbB2 amplification in ovarian cancer","volume":"4","author":"Morali","year":"1993","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/12.suppl_1.S15_bb0085","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/(SICI)1097-0215(19960220)69:1<17::AID-IJC4>3.0.CO;2-Z","article-title":"Concomitant overexpression of the EGFR and erbB-2 genes in renal cell carcinoma (RCC) is correlated with dedifferentiation and metastasis","volume":"69","author":"Stumm","year":"1996","journal-title":"Int J Cancer"},{"key":"10.1093\/annonc\/12.suppl_1.S15_bb0090","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1016\/0046-8177(93)90194-L","article-title":"Overexpression of HER2\/neu oncogene in human pancreatic carcinoma","volume":"24","author":"Yamanaka","year":"1993","journal-title":"Hum Pathol"},{"key":"10.1093\/annonc\/12.suppl_1.S15_bb0095","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1200\/JCO.1996.14.3.737","article-title":"Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2\/neu-overexpressing metastatic breast cancer","volume":"14","author":"Baselga","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/12.suppl_1.S15_bb0100","doi-asserted-by":"crossref","first-page":"2659","DOI":"10.1200\/JCO.1998.16.8.2659","article-title":"Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2\/neu monoclonal antibody plus cisplatin in patients with HER2\/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment","volume":"16","author":"Pegram","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/12.suppl_1.S15_bb0105","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1056\/NEJM199206253262607","article-title":"Prognostic factors and treatment decisions in axillary-node-negative breast cancer","volume":"326","author":"McGuire","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/12.suppl_1.S15_bb0110","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1126\/science.3798106","article-title":"Human breast cancer: Correlation of relapse and survival with amplification of the HER-2\/neu oncogene","volume":"235","author":"Slamon","year":"1987","journal-title":"Science"},{"key":"10.1093\/annonc\/12.suppl_1.S15_bb0115","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1093\/jnci\/85.12.965","article-title":"P53 as an independent prognostic marker in lymph node-negative breast cancer patients","volume":"85","author":"Silverstrini","year":"1993","journal-title":"J Natl Cancer Inst"},{"key":"10.1093\/annonc\/12.suppl_1.S15_bb0120","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/BF00666587","article-title":"Concurrent abnormal expression of ERBB-2, EGFR and p53 genes and clinical disease progression of breast carcinoma","volume":"28","author":"Visscher","year":"1993","journal-title":"Breast Cancer Res Treat"},{"key":"10.1093\/annonc\/12.suppl_1.S15_bb0125","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/ijc.2910490109","article-title":"Prognostic significance of HER2\/neu expression in breast cancer and its relationship to other prognostic factors","volume":"49","author":"Rilke","year":"1991","journal-title":"Int J Cancer"},{"key":"10.1093\/annonc\/12.suppl_1.S15_bb0130","first-page":"193","article-title":"Untangling the multiple prognostic factor problem","volume":"34","author":"Hilsenheck","year":"1993","journal-title":"Proc Am Assoc Cancer Res"},{"key":"10.1093\/annonc\/12.suppl_1.S15_bb0135","first-page":"271","article-title":"Expression of c-erbB-2 oncogene and p53 tumor suppressor gene in benign and malignant breast tissue: Correlation with proliferative activity and prognostic index","volume":"142","author":"Alexiev","year":"1997","journal-title":"Gen Diagn Pathol"},{"key":"10.1093\/annonc\/12.suppl_1.S15_bb0140","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1111\/j.1440-1827.1998.tb03943.x","article-title":"Multiple developmental pathways of highly aggressive breast cancers disclosed by comparison of histological grades and c-erbB-2 expression patterns in both the non-invasive and invasive portions","volume":"48","author":"Tsuda","year":"1998","journal-title":"Pathol Int"},{"key":"10.1093\/annonc\/12.suppl_1.S15_bb0145","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/0046-8177(92)90257-4","article-title":"Overexpression of HER2\/neu and its relationship with other prognostic factors changed during progression of in situ to invasive breast cancer","volume":"23","author":"Allred","year":"1992","journal-title":"Hum Pathol"},{"key":"10.1093\/annonc\/12.suppl_1.S15_bb0150","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/S0959-8049(05)80117-0","article-title":"Overexpression of the c-erbB-2 oncogene: Why does this occur more frequently in ductal carcinoma in situ than in invasive mammary carcinoma and is this of prognostic significance?","volume":"28","author":"Barnes","year":"1992","journal-title":"Eur J Cancer"},{"key":"10.1093\/annonc\/12.suppl_1.S15_bb0155","first-page":"1027","article-title":"The HER2 (c-erbB-2) oncogene is frequently amplified in in situ carcinomas of the breast","volume":"7","author":"Liu","year":"1992","journal-title":"Oncogene"},{"key":"10.1093\/annonc\/12.suppl_1.S15_bb0160","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1159\/000163709","article-title":"Expression of c-erbB-2 in in situ and in adjacent invasive ductal adenocarcinomas of the female breast","volume":"60","author":"Maguire","year":"1992","journal-title":"Pathobiology"},{"key":"10.1093\/annonc\/12.suppl_1.S15_bb0165","first-page":"1001","article-title":"Inhibition of c-erbB-2 oncogene expression by estrogens in human breast cancer cells","volume":"5","author":"Dati","year":"1990","journal-title":"Oncogene"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419544519?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419544519?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/12\/suppl_1\/S15\/6672717\/12-suppl_1-S15.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,26]],"date-time":"2021-12-26T14:21:08Z","timestamp":1640528468000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419544519"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001]]},"references-count":32,"alternative-id":["S0923753419544519"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/12.suppl_1.s15","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2001]]}}}